Abstract

BackgroundBlisibimod, a peptibody that inhibits B-cell activating factor (BAFF), was previously found [1] to be safe, efficacious and well-tolerated in patients with systemic lupus erythematosus (SLE) that participated in a...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
FRI0389 Effects of Chronic Treatment with Subcutaneous Blisibimod on Renal and Inflammation Biomarkers in Subjects with Systemic Lupus Erythematosus in Phase 2 PEARL-SC and Open-Label Extension Studies
...
Annals of the Rheumatic Diseases | VOL. 73
, et. al. ...
01 Jun 2014
Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study
Joseph Yen ... Lanetta Bronté-Hall
Blood | VOL. 138
Joseph Yen, et. al.Joseph Yen ... Lanetta Bronté-Hall
05 Nov 2021
Identification of the intermittent nature of trace mitral and/or aortic regurgitation: long-term longitudinal echocardiogram study in children with Dravet syndrome treated with fenfluramine
M.G Keane ... P Wong
European Heart Journal | VOL. 41
M.G Keane, et. al.M.G Keane ... P Wong
01 Nov 2020
THU0387 Effects of Blisibimod, An Inhibitor of B Cell Activating Factor, On Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus
M Petri ... M.A Scheinberg
Annals of the Rheumatic Diseases | VOL. 74
M Petri, et. al.M Petri ... M.A Scheinberg
01 Jun 2015
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers